NCT02366676View on ClinicalTrials.gov

Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

October 30, 2019

Conditions
Recurrent Cystitis
Interventions
DRUG

hyaluronic acid and chondroitin sulphate

IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)

Trial Locations (1)

130-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02366676 - Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract | Biotech Hunter | Biotech Hunter